Impact of diagnosis-to-ablation time on left atrial remodeling and voltage-guided ablation outcome in persistent atrial fibrillation patients
Frontiers in Cardiovascular Medicine · 12.03.2026 · 13
DOI: 10.3389/fcvm.2026.1751432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 12.03.2026. Verfasst von Halim Marzak und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Delayed catheter ablation (CA) has been associated with higher rates of atrial fibrillation (AF) recurrence. Low-voltage zones (LVZs) are established predictors of AF recurrence after CA. Data on LVZ assessment in relation to diagnosis-to-ablation time (DAT) remain limited. This study aimed to evaluate the extent of left atrial (LA) LVZs, bipolar voltage, and the outcomes of voltage-guided CA in patients with persistent AF, classified according to DAT.
Methods
We consecutively enrolled 350 patients with persistent AF undergoing their first voltage-guided CA. Patients were classified according to DAT into two groups: DAT ≤1 year ( n = 131) and >1 year ( n = 219). LA voltage mapping was performed during sinus rhythm. LVZs were defined as regions with a bipolar voltage <0.5 mV.
Results
Patients with DAT >1 year exhibited lower LA bipolar voltage ( p < 0.01) and larger LA and indexed LA volumes ( p < 0.01). LVZs were more frequent in this group (43% vs. 28%, p = 0.01), particularly moderate LVZs ( p = 0.04). Recurrence of atrial tachyarrhythmias (ATs) after a single procedure occurred more often in patients with DAT >1 year (log-rank p = 0.05). Multivariable analysis revealed that female sex ( p < 0.001), indexed LA volume ≥48 mL/m 2 ( p = 0.008), age ≥60 years ( p < 0.05), and P-wave duration ≥150 ms ( p < 0.001) were independently associated with the presence of LVZs. A history of paroxysmal AF was associated with a lower likelihood of LVZs, whereas DAT was not an independent predictor.
Conclusion
Patients with persistent AF and a longer DAT displayed more extensive LA substrate remodeling. Despite a tailored ablation targeting LVZs, a longer DAT was associated with a higher rate of AT recurrence. Early ablation within the first year after AF diagnosis could optimize AF CA outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.
- UR 3074 Translational CardioVascular Medicine, CRBS, University of Strasbourg, Strasbourg, France.
- Public Health Service, Groupe Méthodes en Recherche Clinique (GMRC), Strasbourg University Hospital, Strasbourg, France.
Zitieren
APA
Marzak, H., Severac, F., Baldacini, C., Fitouchi, S., Faucher, L., Jacques, J., Cardi, T., Kanso, M., Schatz, A., Ohlmann, P., Morel, O., & Jesel, L. (2026). Impact of diagnosis-to-ablation time on left atrial remodeling and voltage-guided ablation outcome in persistent atrial fibrillation patients. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1751432
Vancouver
Marzak H, Severac F, Baldacini C, Fitouchi S, Faucher L, Jacques J, et al. Impact of diagnosis-to-ablation time on left atrial remodeling and voltage-guided ablation outcome in persistent atrial fibrillation patients. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1751432
BibTeX
@article{Marzak2026,
author = {Marzak, Halim and Severac, François and Baldacini, Clément and Fitouchi, Simon and Faucher, Loic and Jacques, Julien and Cardi, Thomas and Kanso, Mohamad and Schatz, Alexandre and Ohlmann, Patrick and Morel, Olivier and Jesel, Laurence},
title = {Impact of diagnosis-to-ablation time on left atrial remodeling and voltage-guided ablation outcome in persistent atrial fibrillation patients},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1751432}
}
EUVIMED